Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Consolidated Net Income rose 3507.51% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 2941.25%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
  • Enanta Pharmaceuticals' Consolidated Net Income amounted to -$18.6 million in Q3 2025, which was up 3507.51% from -$18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Consolidated Net Income's 5-year high stood at -$18.3 million during Q2 2025, with a 5-year trough of -$39.1 million in Q2 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was -$28.6 million (2024), whereas its average is -$28.3 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Consolidated Net Income crashed by 50391.34% in 2021, and later surged by 4199.92% in 2024.
  • Enanta Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then increased by 16.61% to -$18.6 million in 2025.
  • Its Consolidated Net Income stands at -$18.6 million for Q3 2025, versus -$18.3 million for Q2 2025 and -$22.6 million for Q1 2025.